MORF-627 is a highly selective, orally active integrin alphavbeta6 inhibitor. By blocking TGF-beta1 activation and pSMAD2 signaling, MORF-627 significantly reduces collagen deposition, epithelial-mesenchymal transition markers, and structural changes in fibrotic cells. MORF-627 exhibits significant antifibrotic efficacy without genotoxicity in idiopathic pulmonary fibrosis models. However, MORF-627 induces bladder epithelial proliferation and early invasive urothelial carcinoma in cynomolgus monkeys and human cells, and this toxic effect can be reversed by exogenous TGF-beta. MORF-627 can be used for studying the pathological mechanisms of pulmonary fibrosis and evaluating drug safety[1][2][3].
Molekulargewicht:
537.67
CAS Nummer:
[2412688-16-3]
Formel:
C31H40FN3O4
Target-Kategorie:
Integrin,TGF-beta/Smad
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
